Download Lisa Schwartz CV - The Dartmouth Institute

CURRICULUM VITAE
Date Prepared
Name
July 2015
Lisa M. Schwartz, M.D., M.S.
Education
Date
Institution
Degree
1994-1996
Dartmouth College
M.S.
1985-1989
New York University School of Medicine
M.D.
1981-1985
State University of New York
B.A.
Postdoctoral Training
Date
Specialty
Institution
1994-1996
General Internal Medicine Fellow
Veterans Administration Hospital
Dartmouth Medical School
1989-1992
Internal Medicine Residency
Bellevue Hospital / NYU Medical Center
Licensure and Certification
Date
Licensure/Certification
1990
National Board of Medical Examiners Parts I, II, III
1992
American Board of Internal Medicine (Recertified 2002, 2012)
1997
Vermont State Medical License #042-000-9475
Curriculum vitae
Lisa Schwartz
Page 2
Academic Appointments
Date
Academic Title
Institution
2011-Present
Co-director, Center for Medicine in the
Media
The Dartmouth Institute for Health
Policy and Clinical Practice
Lebanon, NH
2009-Present
Professor, Departments of Medicine and
Community and Family Medicine.
Dartmouth Medical School
Hanover, NH
2004-2013
Co-director, VA Outcomes Group
VA Medical Center
White River Junction, VT
2003-2009
Associate Professor, Departments of
Dartmouth Medical School
Medicine /Community and Family Medicine Hanover, NH
2003-2005
VA HSR&D Advanced Career
Development Awardee
VA Medical Center
White River Junction, VT
1999-2003
Assistant Professor, Department of
Community and Family Medicine
Dartmouth Medical School
Hanover, NH
1998-2001
VA HSR&D Career Development Awardee VA Medical Center
White River Junction, VT
1997-2003
Assistant Professor, Department of
Medicine
Dartmouth Medical School
Hanover, NH
1996-Present
Investigator, Norris Cotton Cancer Center
Dartmouth-Hitchcock Medical Center,
Lebanon, NH
1994-1997
Instructor, Department of Medicine
Dartmouth Medical School
Hanover, NH
1992-1994
Teaching Assistant
New York University School of
Medicine, New York, NY
Hospital Appointments
Date
Hospital Title
Institution
1994-2013
Staff Physician, Department of Medicine
VA Medical Center
White River Junction, VT
1992-1994
Primary Care Attending Physician,
Department of Medicine
Gouverneur Hospital
New York, New York
1992-1994
Assistant Attending of Medicine
Bellevue Hospital Medical Center
New York, NY
Curriculum vitae
Lisa Schwartz
Page 3
Other Professional Positions
Date
Position Title
Institution/Organization
2001-2002
Interim Co-editor
Effective Clinical Practice
1998-2001
Associate Editor
Co-editor, Special issue -Decision making
Effective Clinical Practice
(ACP-ASIM peer reviewed journal)
2006-2009
Admissions committee member
The Dartmouth Institute for Health
Policy and Clinical Practice, Masters
Program, Lebanon, NH
2009-2010
Academic, Promotions and Titles
Committee Member
Dartmouth Medical School
2009-2010
Consultant to Cancer Prevention Division
National Cancer Institute
2010-2012
Research Collaboration Agreement
FDA
2010-Present
Ad-hoc Member
Drug Safety and Risk Management
Advisory Committee
FDA
2011-Present
Advisory Board for Enhancing Public
Understanding of Science
International Collaboration,
Oxford, UK
2012-Present
Consultation to SEER
(Risk communication)
National Cancer Institute
2012-Present
Steering Committee Member,
Preventing Overdiagnosis
Co-sponsored by BMJ, Consumer
Reports, Dartmouth, University of
Oxford, Bond University Australia
2013
Advisory Committee Member (Surovexant) FDA
2013-present
Internal AdvisoryBoard
2013-2014
Workshop Steering Committee Collaborator Institute of Medicine's Drug Forum
2014-2015
Consultant
Clinicaltrials.gov
2014
Consultant
JAMA
2014-present
Consultant
Brigham & Women's Hospital
(Aaron Kessleheim/Jerry Avorn)
contract with FDA
Dartmouth CTSA
Curriculum vitae
Lisa Schwartz
Page 4
CURRENT TEACHING RESPONSIBILITIES:
Dartmouth Medical School
Date
Teaching
2000-Present
Co-Course Director, Introduction to Survey Research Methods
The Dartmouth Institute for Health Policy and Clinical Practice, Masters Program
2012-Present
Co-Director, Professional Development Seminar
The Dartmouth Institute for Health Policy and Clinical Practice
National
2002-Present
Curriculum design and teacher, National Institutes of Health, Medicine in the Media:
Workshop for Medical Journalists (on hold until reubudgeting approved at NCI tenatively scheduled to resume 2015)
2003-Present
Workshop teacher (1/2 day session); Medical Evidence Boot Camp for Medical Journalists
Knight Science Journalism Fellowships at Massachusetts Institute of Technology
INVITED PRESENTATIONS
SELECTED RECENT PRESENTATIONS:
Date
Topic
Organization
Location
2009
The effectiveness of the drug FDA, Risk Communication
facts box in communicating
Advisory Committee
the benefits and side effects of
prescription drugs
Washington, DC
2009
Know your chances: A
curriculum to help students
become better consumers of
statistics
2009
Helping journalists effectively National Press Club
communicate the results of
medical research
Washington, DC
2009
How might SEER make
smarter journalists, physicians
and patients?
SEER Visioning Exercise
National Cancer Institute
Bethesda, MD
2010
Communicating the benefits
and harms of prescription
drugs
Medical Grand Rounds
Minneapolis VA Medical Center
Minneapolis, MN
2010
A randomized trial about
communicating numbers and
cautions
National Center Institute
Division of Cancer Prevention
Rockville, MD
2010
Breast cancer and the media:
Who gets it right?
National Breast Cancer Coalition
Washington DC
National Meeting of the American Washington, DC
Statistical Association
Curriculum vitae
Lisa Schwartz
Page 5
2010
The drug facts box:
Communicating the benefits
and harms of prescription
drugs
Evidence 2010
British Medical Journal
London, UK
2011
The drug facts box:
National Health Service Choices
London, UK
2011
The drug facts box
Center for Medicaid and Medicare Baltimore, MD
Services
2011
Bad news and good news
National Cancer Institute
Prevention Fellows
Bethesda, MD
2011
Understanding the facts when
reporting on breast cancer
National Breast Cancer Coalition
New York, NY
2012
Generating the science needed National Academy of Sciences
for relevant communication
Washington, DC
2013
"Continuish" outcomes
JAMA/BMJ Peer Review
Congress
Chicago, IL
2013
Overdiagnosis (plenary)
Cochrane Collaboration
Oxford, UK
2013
Making sense of medical
information
New England Association of
Medical Librarians
Woodstock, NY
2014
Overdiagnosis (plenary)
Israeli National Association of
Family Physicans
Tel Aviv, Israel
2014
Communicating uncertainty
IOM/FDA
about the benefits and harms of
pharmaceutical products
Silver Spring, MD
Media analysis: Tysabri case
study
2014
Communicating uncertainty
about new drugs
AAAS/Brigham & Women's
Hospital
Washington, DC
2015
FDA and the media: Lessons
from Tysabri
IOM Drug Forum
Washington, DC
Curriculum vitae
Lisa Schwartz
Page 6
MAJOR RESEARCH INTERESTS
My research addresses the excessive fear and hope created by exaggerations, distortions, and selective
reporting in medical journals, advertising, and health news. My goal is to improve the communication
of medical evidence about cancer screening and prescription drugs to physicians, journalists, and the
public. Together with the NIH, I have run the health journalist workshop “Medicine in the Media: The
challenges of reporting on medical research” for the past 11 years and organized the first scientific
conference on Overdiagnosis held at Dartmouth (co-sponsored by Dartmouth, BMJ and Consumer
Reports), co-authored 2 books: Know Your Chances (selected for the NLM bookshelf) and
Overdiagnosed. I have collaborated with the FDA's Center for Drug Evaluation and Research to develop
better prescription drug information and the National Cancer Institute to develop better presentations of
cancer statistics.
RESEARCH FUNDING:
1. Enhancing informed decision making about mammography (1996-2001), Department of
Defense Breast Cancer Research Program, New Investigator Award (4 years), (Joint
principal investigator)
2. Department of Veterans Affairs Health Services Research & Development (Level I), Career
Development Award (1998-2001) Full salary support (Principal investigator)
3. Understanding numbers and health: A primer for patients (2000-2005), R18 National Cancer
Institute (2 years) (Joint principal investigator)
4. Department of Veterans Affairs Health Services Research & Development, Advanced Career
Development Award (2002-2005) Full salary support (Principal investigator)
5. Volume matters: Helping patients pick hospitals. R03 AHRQ (2002-2003) (Co-principal
investigator)
6. Simple tools to facilitate risk communication in primary care, Robert Wood Johnson
Generalist Faculty Scholar Program (2002-2006) (Principal investigator)
7. Center to address harm from medical care, VA HSR&D REAP Application (4/03-9/08) (Coinvestigator)
8. Helping physicians critically evaluate drug information: A curriculum and method for
enhancing sensible decision making during office visits, State of Oregon, Prescriber and
Consumer Education Grant (7/06-6/09) (Joint principal investigator)
9. Improving the quality of news media reporting on medicine, R01 NIH (7/04-6/10) (Joint
principal investigator)
10. The prescription drug facts box. Robert Wood Johnson Pioneer Program (8/08-2/12) (Joint
Principal Investigator)
11. .Incidence of pulmonary nodules and downstream resource use in the VA. VA Health
Services Research & Development Merit Review (10/08-6/12). Principal Investigator:
Curriculum vitae
Lisa Schwartz
Page 7
Steven Woloshin, Co-Principal Investigator: Renda Wiener. Co-Investigator: Lisa M.
Schwartz.
12. Bringing drug facts boxes to the public: Developing a self-sustaining model. Robert Wood
Johnson Pioneer Program (11/11 – 4/13) ) (Joint Principal Investigator)
13. Making drug facts boxes available to the public through a self-sustaining business model
Robert Wood Johnson Pioneer Program (12/12 – 11/13 ) (Joint Principal Investigator)
BIBLIOGRAPHY
Original Articles
1. Woloshin S, Bickell NA, Schwartz LM, Gany F, Welch HG. Language barriers in medicine in
the United States. JAMA 1995; 273: 724-728. [Response to letters: JAMA 1995; 274:684]
2. Schwartz LM, Woloshin S, Welch HG. Trends in diagnostic testing following a national
guideline for evaluation of dyspepsia. Arch Intern Med 1996; 156:873-875.
3. Schwartz LM, Fisher ES, Tosteson AN, Woloshin S, Chiang CH, Plohman J, Vernig B, Wright,
B. Treatment and health outcomes of women and men in a cohort with coronary artery disease.
Arch Intern Med. 1997; 157: 1545-1551
4. Woloshin S, Schwartz LM, Katz S, Welch HG. Is language a barrier to the use of preventive
services? J Gen Intern Med 1997; 12(8):472-7.
5. Woloshin S, Schwartz LM, Tosteson AN, Chiang CH, Wright B, Plohman J, Fisher ES.
Tangible social support and health outcomes in patients with coronary artery disease. J Gen Intern
Med. 1997; 12(10):613-8.
6. Schwartz LM, Woloshin S, Black WC, Welch HG. The role of numeracy in understanding the
benefit of screening mammography. Ann Intern Med 1997; 127: 966-972.
7. Schwartz LM, Woloshin S, Renfrew R, Wasson JH, Welch HG. Setting the revisit interval in
primary care. J Gen Intern Med 1999; 14: 230-235.
8. Welch HG, Chapko M, James, Schwartz LM, Woloshin. The role of patients and providers in
the timing of follow-up visits J Gen Intern Med 1999; 14:223-229.
9. Schwartz LM, Woloshin S. Changing disease definitions: Implications on disease prevalence.
Eff Clin Pract 1999; 2:76-85.
10. Woloshin S, Schwartz LM. The US Postal Service and cancer screening: Stamps of approval?
N Engl J Med 1999; 340: 884-887. [Response to letters: N Engl J Med 1999; 341: 543]
11. Woloshin S, Schwartz LM, Black WC, Welch HG. Women's perceptions of breast cancer risk:
How you ask matters. Med Decis Making 1999; 19: 221-229.
12. Woloshin S, Schwartz LM. How can we help patients make sense of medical data? Eff Clin
Pract 1999; 2:176-183.
13. Schwartz LM, Woloshin S, Welch HG. Misunderstandings about the effect of race and sex on
physicians' referrals for cardiac catheterization. N Engl J Med 1999; 341:279-283. [Response to
letters: N Engl J Med 1999; 341: 2022]
Curriculum vitae
Lisa Schwartz
Page 8
14. Schwartz LM, Woloshin S, Welch HG. Risk communication in clinical practice: Putting cancer
in context. Monogr Natl Cancer Inst 1999; 25:124-33.
15. Woloshin S, Schwartz LM, Byram SJ, Sox HC, Fischhoff B, Welch HG. Women's
understanding of the mammography screening debate. Arch Intern Med 2000;160:1434-1440.
16. Welch HG, Schwartz LM, Woloshin S. Are changing five year survival rates evidence of
progress against cancer? JAMA 2000; 283:2975-2984. [Response to letters: JAMA 2000; 284:
2054-55.
17. Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women's attitudes to false
positive mammography results and detection of ductal carcinoma in situ: cross sectional survey.
BMJ 2000; 320:1635-1640. [Response to letters: BMJ 2000:321: 1049]
18. Reprinted: Schwartz LM, Woloshin S, Sox HC, Fischhoff B, Welch HG. US women's attitudes
to false positive mammography results and detection of ductal carcinoma in situ: cross sectional
survey. West J Med 2000; 173:307-12.
19. Woloshin S, Schwartz LM, Byram SB, Fischhoff B, Welch HG. A new scale for assessing
perceptions of chance: A validation study. Med Decis Making 2000;20:298-307
20. Zacharski L, Ornstein DL, Woloshin S, Schwartz LM. The association of age, sex and race with
body iron stores in adults: Analysis of NHANES III Data. Am Heart J 2000;140:98-104.
21. Silverman E, Woloshin S, Schwartz LM, Byram SJ, Welch HG, Fischhoff B. Women’s Views
on Breast Cancer Risk and Screening Mammography: A qualitative interview study. Med Decis
Making 2001;21:231-40.
22. Woloshin S, Schwartz LM, Moncur M, Gabriel S, Tosteson ANA. Assessing values for health:
Numeracy matters Med Decis Making 2001; 21:382-390.
23. Woloshin S, Schwartz LM, Tremmel J, Welch HG. Direct to consumer drug advertisements:
What are Americans being sold? Lancet 2001; 358:1141-6.
24. Liu JY, Woloshin S, Laycock WS, Schwartz LM. Late outcomes after laparoscopic surgery for
gastroesophageal reflux. Arch Surg 2002;137:397-401.
25. Schwartz LM, Woloshin S. msJAMA-Marketing medicine to the public: A reader's guide.
JAMA 2002; 287:774-775.
26. Woloshin S, Schwartz LM, Welch HG. Tobacco money: Up in smoke? Lancet 2002; 359:
2108-2111. [Response to letters: Lancet 2002;360:954]
27. Schwartz LM, Woloshin S, Baczek L. Media coverage of scientific meetings: Too much, too
soon? JAMA 2002;287:2859-63
28. Woloshin S, Schwartz L. Press releases: Translating research into news. JAMA
2002;287:2856-8.
29. Woloshin S, Schwartz LM, Welch HG. Risk charts: Putting cancer in context. J Natl Cancer
Inst 2002; 94:799-804. [Response to letters: J Natl Cancer Inst 2002; 94: 1585-1586.]
30. Schwartz LM, Woloshin, S. News media coverage of screening mammography for women in
their forties and tamoxifen for primary prevention of breast cancer. JAMA 2002;287:3136-3142.
31. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colon cancer: Does
Curriculum vitae
Lisa Schwartz
Page 9
practice match evidence? JAMA 2003; 289:1414-20.
32. Schwartz LM, Woloshin S, Fowler FJ, Welch HG. Enthusiasm for cancer screening in the
United States. JAMA 2004; 291:71-8. [Response to letters: JAMA 2004; 291:1836.
33. Caudhill-Slosberg M, Schwartz LM, Woloshin S. National trends in office visits and analgesic
prescriptions for musculoskeletal pain: 1980 vs. 2000. Pain 2004: 109:514-19.
34. Woloshin S, Schwartz LM, Welch HG. The value of benefit data in direct-to-consumer drug ads.
Health Affairs 2004: W234-245. Accompanying editorials by FDA (Peter Pitts), Senator James
Jeffords, Representative Henry Waxman, Eli Lilly and Pfizer.
35. Liu J, Woloshin S, Laycock W, Rothstein, RI, Finlayson S, Schwartz LM. Validating the GERD
Assessment Scales(GAS): Measuring the symptom and treatment burden of GERD. Arch Intern
Med 2004; 164:2058-2064.
36. Sirovich B, Woloshin S, Schwartz LM. Screening for cervical cancer: Will women accept less?
Am J Med 2005; 118:151-158.
37. Larson, R, Schwartz LM, Woloshin S, Welch HG. Advertising by Academic Medical Centers.
Arch Intern Med. 2005; 165:1-7.
38. Welch HG, Schwartz LM, Woloshin S. Exaggerated relationship between diet, body weight and
mortality: The case for a categorical data approach. Can Med Assn J 2005;891-95.
39. Larson, R, Schwartz LM, Woloshin S, Welch HG. Celebrity endorsements of cancer screening.
J Natl Cancer Inst 2005;97:693-5.
40. Schwartz LM, Woloshin S, Welch HG. Can patients interpret health information? An
assessment of the medical data interpretation test. Med Dec Making. 2005;25:290-300.
41. Welch HG, Schwartz LM, Woloshin S. Prostate specific antigen levels in the United States:
Implications of various definitions for abnormal. J Natl Cancer Inst 2005; 97:1132-7.
42. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and the incidence of melanoma.
population based ecological study BMJ 2005; 331:481-5.
43. Schwartz LM, Woloshin S, Birkmeyer JB. How do elderly patients decide where to go for major
surgery? Telephone interview survey BMJ 2005; 331:821-4.
44. Woloshin S, Schwartz LM, Welch HG. Patients and medical statistics: Interest, confidence and
ability. J Gen Intern Med 2005; 20:996-1000.
45. Woloshin S, Schwartz LM. Giving legs to restless legs: A case study of how the media helps
make people sick. PLoS Med 2006 3(4) e170: 0452-0455.
46. Woloshin S, Schwartz LM. Media reporting on scientific meeting presentations: More caution
needed. MJA 2006; 184(11):576-580.
47. Schwartz LM, Woloshin S, Dvorin EL, Welch HG. Ratio measures in leading medical journals:
structured review of accessibility of underlying absolute risks. BMJ 2006 333:1248-50.
48. Woloshin S, Schwartz LM, Welch HG. The effectiveness of a primer to help people understand
risk: Two randomized trials in distinct populations. Ann Intern Med 2007 146:256-265
49. Wilson, CT, Woloshin, S, Schwartz LM. Choosing where to have major surgery: Who decides?
Arch Surgery 2007 142:242-246.
50. Woloshin S, Schwartz LM, Kerin K, Welch HG. Estimating the impact of adding C-reactive
protein as a criterion for lipid lowering treatment in the United States J Gen Intern Med 2007
Curriculum vitae
Lisa Schwartz
Page 10
22:197-204
51. Kallen AJ, Shu JA, Juhl EL, Woloshin S, Schwartz LM. Direct-to-consumer advertisements for
HIV antiretroviral medications: A progress report. Health Affairs 2007 26:1392-1398.
52. Schwartz LM, Woloshin S, Welch HG. The drug facts box: Providing consumers with simple
tabular data on drug benefit and harm. Med Decis Making 2007;27:655-662.
53. Herndon, MB, Schwartz LM, Woloshin S, Welch HG. Implications of expanding disease
definitions: The case of osteoporosis. Health Affairs 2007; 26: 1702-1711.
54. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gotzsche PC, Harris R, Kramer BS,
Ransonhoff DF. Overstating the evidence for lung cancer screening: The I-ELCAP study. Arch
Intern Med 2007;167(21):1-7.
55. Woloshin S, Schwartz LM, Welch HG. The risk of death by age, sex, and smoking status in the
United States: Putting health risks in context. J Natl Cancer Inst. 2008; 100: 845 - 853.
56. Herndon B, Schwartz LM, Woloshin S, Anthony D, Gallagher P, Fowler FJ, Fisher ES. Older
patient's perceptions of "unnecessary" test and referrals: A national survey of Medicare
beneficiaries. J Gen Intern Med 2008; 23:1547-54.
57. Gigerenzer G, Gaissmaier W, Kurze-Milcke Elke, Schwartz LM, Woloshin S Knowing your
chances: What health stats really mean Scientific American Mind April 2009
58. Schwartz LM, Woloshin S, Welch HG. Communicating drug benefits and harms with the drug
facts box: Two randomized trials. Ann Intern Med 2009 150: 516-527.
59. Woloshin S, Schwartz LM, Cassela S, Kennedy A, Larson RJ. Academic medical center press
releases: Not so academic? Ann Intern Med 2009 150: 613-618
60. Wallace D, Rheinlander K, Woloshin S, Schwartz LM. Quantitative literacy assessments: An
introduction to testing tests. Numeracy 2009 Iss 2, Article 3.
61. Schwartz LM, Woloshin S. Lost in transmission – FDA drug information that never reaches
clinicians. N Engl J Med 2009; 361: 1717-1720.
62. Cordoba G, Schwartz LM, Wolsohin S, Bae H, Goetzsche PC. Definition, reporting and
interpretation of composite outcomes in clinical trials: Systematic review. BMJ 2010 341:C3920.
63. Siegel CA, Schwartz LM, Woloshin S, Cole EB, Rubin DT, Vay T, Baars J, Sands BE. When
should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient
preferences and physician recommendations. Inflamm Bowel Dis 2010;16:1658-62.
64. Wiener RS, Schwartz LM, S Woloshin. Time Trends in Pulmonary Embolism in the United
States: Evidence of Overdiagnosis. Arch Intern Med 2011;171:831-837.
65. Woloshin S, Schwartz LM. Communicating data about the benefits and harms of treatment: A
randomized trial. Ann Intern Med 2011:155:87-96.
66. Wiener R, Schwartz LM, Wolos21hin S, Welch. Population-based risk for complications after
transthoracic needle lung biopsy. Ann Intern Med 2011: 155: 137-44.
67. Schwartz LM, Woloshin, S. Communicating uncertainties about prescription drugs to the public.
A national randomized trial. Arch Intern Med 2011:171:1463-1468
68. Sirovich BE, Woloshin S, Schwartz LM. Too little? Too much? Primary care physicians' view
on US Health Care. Arch Intern Med 2011:171:1582-1585.
Curriculum vitae
Lisa Schwartz
Page 11
69. Schwartz LM, Woloshin S, Andrews A, Stukel TA. Influence of medical journal press releases
on the quality of associated newspaper coverage: retrospective cohort study. BMJ 2012;
344:d8164.
70. Wegwarth O, Schwartz LM, Woloshin S, Gaissmeier W, Gigerenzer G. Do physicians
understand cancer screening statistics? A national survey of primary care physicians in the United
States. Ann Intern Med 2012; 156:340-349.
71. Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. "The thing is not knowing":
patients' perspectives on surveillance of an indeterminate pulmonary nodule. Health Expect.
2012 doi: 10.1111/hex.12036
72. Wiener RS, Gould MK, Woloshin S, Schwartz LM, Clark JA. "What do you mean, a spot?". A
qualitative analysis of patients' reactions to discussions with their doctors about pulmonary
nodules. Chest 2012 doi: 10.1373/chest.12-1095.
73. Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns – getting past
uninformative persuasion. N Engl J Med 2012; 367:1677-1679.
74. Schwartz LM, Woloshin S. The Drug Facts Box: Improving the communication of prescription
drug information, Proc Nat Acad Sci 2013 , Proc Nat Acad Sci 2013.
www.pnas/cgi/doi/10.1073/pnas.1214646110
75. Wiener RS, Schwartz LM, Woloshin S. When a test is too good: How CT pulmonary
angiograms find pulmonary emboli that do not need to be found. BMJ 2013 346:3368 doi:
10.1136/bmj.f3368.
76. Morden, N. Schwartz LM, Fisher ES, Woloshin S. Accountable prescribing. N Engl J Med
2013 369:229-302.
77. Woloshin S, Schwartz LM, Dann E, Black WC. Using radiology reports to encourage evidencebased practice in the evaluation of small incidentally detected pulmonary nodules: A preliminary
study. Annals ATS 2013 doi 10.1513/AnnalsATS.201307-242BC
78. .Weiner RS, Gould, MK Slatore CG, Fincke BG, Schwartz LM, Woloshin S. Resource Use and
Guideline Concordance in Evaluation of Pulmonary Nodules for Cancer: Too Much and Too
Little Care. JAMA Intern Med 2014 Apr 7. doi: 10.1001/jamainternmed.2014.561
79. Woloshin S, Schwartz LM. The new weight-loss drugs, lorcaserin and phentermine-topiramate:
slim pickings? JAMA Intern Med 2014 Apr 1;174(4):615-9. doi:
10.1001/jamainternmed.2013.14629.
80. Howlander N, Mariotto AB, Woloshin S, Schwartz LM. Providing clinicians and patients with
actual prognosis: Cancer in the context of competing causes of death. J Natl Cancer Inst
(Survival Monograph) 2014;49:255-264.
81. Cho H, Mariotto AB, Schwartz LM, Luo J, Woloshin S. When do changes in cancer survival
mean progress? The insight from population incidence and mortality. J Natl Cancer Inst (Survival
Monograph) 2014. 49:187-197.
82. Mariotto AB, Noone A, Howlander N, Cho H, Woloshin S, Schwartz LM. Cancer Survival: An
overview of measures, uses and interpretation J Natl Cancer Inst (Survival Monograph)
2014:49:145-186.
83. Woloshin S, Schwartz LM, Frankel B, Faerber A. FDA and the design of drug approval studies.
Curriculum vitae
Lisa Schwartz
Page 12
JAMA 2014: 312: 263-265.
84. Kesselheim AS, Campbell EG, Schneeweiss S, Rausch P, Lappin BM, Zhou EH, Seeger JD,
Brownstein JS, Woloshin S, Schwartz LM, Toomey T, Dal Pan GJ, Avorn J. Methodological
approaches to evaluate the impact of FDA drug safety communications. Drug Saf 2015 38:565-75
85. Simmons J, Gould MK, Woloshin S, Schwartz LM, Wiener RS. Attitudes about low-dose
computed tomography screening for lung cancer: a survey of American Thoracic Society
Clinicians. Am J Resp Crit Care Med 2015 191:483-6.
BMJ Occasional Column: Not So Stories
1. Schwartz LM, Woloshin S. How the FDA forgot the evidence: The case of donepezil 23mg.
BMJ 2012;344:e1086
2. Woloshin S, Schwartz LM. How a charity oversells mammography. BMJ 2012;345:e5132.
Monograph
1. Gigerenzer G, Gaissmaier W, Kurze-Milcke Elke, Schwartz LM, Woloshin S. Helping doctors
and patients make sense of health statistics. Psychological Science in the Public Interest (A
journal of the Association for Psychological Science) 2008; Vol 8.
Editorials
1. Schwartz LM, Woloshin S. Patient decision making: In search of good decisions. Eff Clin
Pract 1999; 2:184.
2. Schwartz LM, Woloshin S. Are health-oriented stamps bad medicine?. Physician's Weekly
Vol. XVI, No.27, July 19, 1999
3. Woloshin S, Schwartz LM Early stage breast cancer treatment for elderly women: Does one
size fit all? Surgery 2000; 128:865-7.
4. Schwartz LM, Woloshin S. The case for letting information speak for itself. Eff Clin Pract
2001; 4:76-79.
5. Woloshin S, Schwartz LM. Smoke-free movies: sense or censorship?. Eff Clin Pract 2002;
5:29-30.
6. Schwartz LM, Woloshin S. On the prevention and treatment of exaggeration. J Gen Intern Med
2003; 18: 153-154.
7. Woloshin S, Schwartz LM, Ellner A. Making sense of risk information on the web: Don't
forget the basics. BMJ 2003. 327:695-6.
8. Schwartz LM, Woloshin S. The media matters: A call for straightforward medical reporting
Ann Intern Med 2004; 140: 226-228.
9. Woloshin S, Schwartz LM. Reducing the risk that patients get it wrong. Gastroenterology
2005; 129:748-50.
10. Woloshin S, Schwartz LM. What's the rush? The dissemination and adoption of preliminary
research findings. J Natl Cancer Inst 2006; 98:372-373.
11. Schwartz LM, Woloshin S. Participation in mammography screening. BMJ 2007; 335:731-2.
Curriculum vitae
Lisa Schwartz
Page 13
12. Welch HG, Woloshin S, Schwartz LM. The sea of uncertainty surrounding DCIS: The price of
screening mammography. J Natl Cancer Inst 2008; 100:228-229.
13. Schwartz LM, Woloshin S, Moynihan R. Who's watching the watchdogs: Medical journalism
and entanglement. BMJ 2008;337:a2535
14. Woloshin S, Schwartz LM. Numbers needed to decide. J Natl Cancer Inst 2009; 10:1163-65.
15. Woloshin S, Schwartz LM, Kramer BS. Promoting healthy skepticism in the news: Helping
journalists get it right. J Natl Cancer Inst 2009; 101: 1596-1599.
16. Woloshin S, Schwartz LM. Bringing FDA's information to market. Arch Intern Med 2009;169:
1985-1987.
17. Woloshin S, Schwartz LM. The benefits and harms of mammography screening: Understanding
the tradeoffs. JAMA 2010 303: 164-5.
18. Schwartz LM, Woloshin S, Welch HG. Not so silver lining. Arch Intern Med 2011:171:489490.
19. Woloshin S, Schwartz LM. Getting to better prescription drug information J Gen Intern Med.
2012 27: 1582-4.
20. Moynihan R, Glasziou P, Woloshin S, Schwartz LM, Santa J, Godlee F. Winding back the
harms of too much medicine. BMJ 2013 346:f1271/bmj.f1271
21. Schwartz LM, Woloshin S. Low “T” as in Template: How to Sell Disease JAMA-Intern Med.
2013 173:1460-2.
22. Schwartz LM, Woloshin S. Medical communication companies and continuing medical
education: Clouding the sunshine? JAMA. 2013 310: 2507-2508.
23. Brodersen J, Schwartz LM, Woloshin S. Overdiagnosis: How cancer screening can turn
indolent pathology into illness. APMIS 2014 doi: 10.1111/apm.12278.
24. Schwartz LM, Woloshin S. Men's health weak? Evidently Cochrane
(http://www.evidentlycochrane.net/testosterone/)
Book
1. Woloshin, S, Schwartz LM, Welch HG. Know your chances: Understanding health statistics.
University of California Press (November 2008). Selected for the NLM bookshelf /PubMed
Health.
2. Welch HG, Schwartz LM, Woloshin S. Overdiagnosis: How the pursuit of health can make you
sick. Beacon Press (January 2011)
Book Chapters
1. Moynihan R, Schwartz LM, Woloshin S. Medicine/s and the media: Good information or
misleading hype. In British Medical Journal publication "Evaluating pharmaceuticals for Health
Curriculum vitae
Lisa Schwartz
Page 14
Policy and Reimbursement. Edited by N. Freemantle, S. Hill., Blackwell Publishing Ltd,
Oxford, UK. 2004.
2. Byram SJ, Schwartz LM, Woloshin S, Fischhoff B. Women's beliefs about breast cancer risk
factors: A mental models approach. In Rationality and social responsibility: Essays in honor of
Robyn Mason Dawes. Edited by J. Krueger. Psychology Press. 2008
3. Woloshin S, Schwartz LM. Helping consumers understand the benefits and harms of
prescription drugs. In "Shared decision making in health care: achieving evidence based patient
choice, 2nd edition" by Adrian Edwards and Glyn Elwyn. Oxford University Press. 2009.
4. Schwartz LM, Woloshin S. The drug facts box: Making informed decisions about prescription
drugs possible. In "Better doctors, better patients, better decisions: Envisioning health care
2020" Edited by G Gigerenzer, M Gray. Strungmann Forum Report, Volume 6 MIT Press
(Cambridge, MA)
Publications in the Lay Media
1. Woloshin S, Schwartz LM. We should stamp out this medical misinformation. Los Angeles
Times June 28, 1999, page A15.
2. Woloshin S, Schwartz LM, Welch, HG. Healthy Skepticism (occasional column): Where the
naproxen story went wrong. Washington Post February 1, 2005 page E1.
(http://www.washingtonpost.com/wp-dyn/articles/A52625-2005Jan31.html)
3. Schwartz LM, Woloshin S, Welch HG. Healthy Skepticism (occasional column): Overstating
the benefit of aspirin for breast cancer. Washington Post. May 10, 2005, page F1, F4
4. Woloshin S, Schwartz LM. What's needed on prescription labels. The Boston Globe April 21,
2005, page A23. (Reprinted in the Valley News (4/29/05), Union Leader (5/2/05).
5. Woloshin S, Schwartz LM, Welch HG. Survival is the wrong statistics to track "War on
Cancer". The Cancer Letter, July 29, 2005, page 6-7.
6. Woloshin S, Schwartz LM, Welch HG. Warned, but worse off. The New York Times. August
22, 2005, page A13.
7. Woloshin S, Schwartz LM, Welch HG. Healthy Skepticism (occasional column): A shot of
fear. Washington Post. October 25, 2005, pages F1, F4.
8. Welch HG, Schwartz LM, Woloshin S. What’s making us sick is an epidemic of diagnoses.
New York Times January 2, 2006, page D5.
9. Schwartz LM, Woloshin S, Welch HG. Healthy Skepticism (occasional column): Fat or
fiction. Washington Post. March 14, 2006, page F1, F4
10. Welch HG, Woloshin S, Schwartz LM. Why two studies on cancer screening led to two
different results. New York Times March 13, 2007. page F5, F8
11. Welch HG, Schwartz LM, Woloshin S. Finding more cancer isn’t the answer. Washington Post
Curriculum vitae
Lisa Schwartz
Page 15
April 10, 2007. page F2.
12. Welch HG, Woloshin S, Schwartz LM. Healthy Skepticism. Boston Globe January 1, 2008, p.
A13.
13. Woloshin S, Schwartz LM. Does prostate screening make sense for you? The Boston Globe,
September 29, 2008. p.A11, A13.
14. Woloshin S, Schwartz LM. The EARLY Act is not what the doctor ordered. Los Angeles
Times. July 31, 2009.
15. Woloshin S, Schwartz LM. Think inside the box. New York Times. July 5, 2011. Op-Ed
A21.
16. Schwartz LM, Woloshin S. Endless screenings don't bring everlasting health. New York
Times. April 16, 2012. Science Times D5.
17. Woloshin S, Schwartz LM. 'Low T' and the peril of medicating grumpy old men. The Los
Angeles Times. February 26 2014
18. Woloshin S, Schwartz LM. Sell a disease to sell a drug. Op-Ed. Washington Post June 7,
2015